Abuzan, Mihaela
Surugiu, Roxana
Wang, Chen
Mohamud-Yusuf, Ayan
Tertel, Tobias
Catalin, Bogdan
Doeppner, Thorsten R.
Giebel, Bernd
Hermann, Dirk M. http://orcid.org/0000-0003-0198-3152
Popa-Wagner, Aurel http://orcid.org/0000-0003-4574-8605
Funding for this research was provided by:
German Federal Ministry of Education and Science (161L0278, 161L0278, 161L0278)
PNRR (760058, 760058)
Deutsche Forschungsgemeinschaft (514990328)
Universitätsklinikum Essen
Article History
Received: 4 March 2024
Revised: 18 May 2024
Accepted: 30 May 2024
First Online: 7 September 2024
Declarations
:
: DMH and BG hold patents for the application of extracellular vesicles for the treatment of inflammatory conditions (EP2687219A1; US9877989B2).
: The experiments conducted at the University of Medicine and Pharmacy Craiova received approval from the Institutional Animal Care and Use Committee (#112–15-11–2017). The experiments were carried out in accordance with national regulations in accordance with the EU Directive 2010/63/EU on the care and use of laboratory animals. Randomization of experiments was strictly implemented following the ARRIVE criteria to ensure unbiased data analysis, including behavioral tests, while the examiners involved were kept completely blinded to the experimental conditions. The authors will provide supporting data upon reasonable request to support the conclusions derived from this study.
: N/A.
: DMH and BG hold patents for the application of extracellular vesicles for the treatment of inflammatory conditions (EP2687219A1; US9877989B2).